ProKidney Corp. Files 8-K with Regulatory Updates

Ticker: PROK · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1850270

Prokidney Corp. 8-K Filing Summary
FieldDetail
CompanyProkidney Corp. (PROK)
Form Type8-K
Filed DateJun 10, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-event, regulatory-filing, company-update

Related Tickers: PROK

TL;DR

PROK files 8-K: regulatory updates, former name Social Capital Suvretta Holdings.

AI Summary

ProKidney Corp. filed an 8-K on June 10, 2024, to report on various events. The filing includes information related to Regulation FD disclosure, other events, and financial statements and exhibits. The company was formerly known as Social Capital Suvretta Holdings Corp. III until a name change on March 10, 2021.

Why It Matters

This 8-K filing provides important updates and disclosures for ProKidney Corp., which could impact investor understanding of the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting various corporate events and disclosures, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

  • PROKIDNEY CORP. (company) — Registrant
  • June 10, 2024 (date) — Date of Report
  • Social Capital Suvretta Holdings Corp. III (company) — Former Company Name
  • March 10, 2021 (date) — Date of Name Change

FAQ

What is the primary purpose of this 8-K filing for ProKidney Corp.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was ProKidney Corp. previously known by another name?

ProKidney Corp. was formerly known as Social Capital Suvretta Holdings Corp. III until a name change on March 10, 2021.

What is ProKidney Corp.'s principal executive office address?

ProKidney Corp.'s principal executive office is located at 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina, 27103.

What is the SIC code for ProKidney Corp.?

The Standard Industrial Classification (SIC) code for ProKidney Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

What is the SEC file number for ProKidney Corp.?

The SEC file number for ProKidney Corp. is 001-40560.

Filing Stats: 1,537 words · 6 min read · ~5 pages · Grade level 14.5 · Accepted 2024-06-10 08:00:36

Key Financial Figures

  • $0.0001 — ch registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq

Filing Documents

Forward Looking Statements

Forward Looking Statements This disclosure in this report contains includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the potential of rilparencel to preserve kidney function in patients with moderate to severe CKD, the potential QP Declaration of Equivalence to EU GMPs, the potential benefits and impact of the Company's products, if approved, and potential regulatory approvals. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A ordinary shares on the Nasdaq; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-lice

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated June 10, 2024 99.2 Investor Presentation dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: June 10, 2024 By: /s/ James Coulston James Coulston Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.